The Ritter Pharmaceuticals Inc (RTTR) Raised to “Hold” at The Zacks Investment Research

The Ritter Pharmaceuticals Inc (RTTR) Raised to “Hold” at The Zacks Investment Research

Zacks Investment Research upgraded shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) from a sell rating to a hold rating in a report published on Wednesday.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Other equities research analysts have also recently issued reports about the stock. Chardan Capital raised their price target on shares of Ritter Pharmaceuticals from $3.00 to $3.30 and gave the stock a buy rating in a research note on Tuesday, October 25th. Aegis reaffirmed a buy rating and set a $9.00 price target on shares of Ritter Pharmaceuticals in a research note on Tuesday, October 18th. Finally, Maxim Group reissued a buy rating on shares of Ritter Pharmaceuticals in a research report on Monday, October 17th.

Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 2.38 on Wednesday. The firm’s 50-day moving average is $1.92 and its 200 day moving average is $1.63. Ritter Pharmaceuticals has a 12-month low of $0.98 and a 12-month high of $3.26. The firm’s market cap is $20.43 million.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.14. Equities research analysts predict that Ritter Pharmaceuticals will post ($1.80) EPS for the current year.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Related posts

Leave a Comment

The Ritter Pharmaceuticals Inc (RTTR) Raised to Hold at The Zacks Investment Research

The Ritter Pharmaceuticals Inc (RTTR) Raised to Hold at The Zacks Investment Research

Zacks Investment Research upgraded shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) from a sell rating to a hold rating in a research note issued to investors on Wednesday.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Several other equities research analysts have also commented on the stock. Maxim Group reaffirmed a buy rating on shares of Ritter Pharmaceuticals in a research report on Monday, October 17th. Chardan Capital increased their target price on shares of Ritter Pharmaceuticals from $3.00 to $3.30 and gave the stock a buy rating in a report on Tuesday, October 25th. Finally, Aegis reissued a buy rating and issued a $9.00 target price on shares of Ritter Pharmaceuticals in a report on Tuesday, October 18th.

Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 2.49 on Wednesday. The stock’s market cap is $21.37 million. Ritter Pharmaceuticals has a 52 week low of $0.98 and a 52 week high of $3.26. The firm has a 50-day moving average price of $1.89 and a 200 day moving average price of $1.62.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.14. On average, analysts forecast that Ritter Pharmaceuticals will post ($1.80) EPS for the current fiscal year.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Related posts

Leave a Comment